The Cancer Advisor

Summit Therapeutics' shares were down more than 26% on May 30, 2025 trading after the company said its late-stage study of ivonescimab plus chemotherapy met the progression-free survival primary endpoint in patients with EGFR-mutated non-small cell lung cancer. The treatment reduced the risk of disease progression or death by 48% compared to chemotherapy alone, with consistent results seen across Asian and non-Asian subgroups, Summit said. A positive trend was observed in overall survival, though the data did not meet statistical significance, the company said. Adverse events in the ivonescimab arm were in line with expectations and manageable, Summit said, with no new safety issues identified. The company said it plans to file a Biologics License Application in the US, pending further evaluation and discussions with the US Food and Drug Administration. Source:  https://www.tradingview.com/news/mtnewswires.com:20250530:A3388371:0/ ** Shares of drug developer Summit Therapeutics fal...

Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...

Anti-parasitic drugs such as ivermectin, fenbendazole, and mebendazole have shown promising potential in cancer therapy by disrupting cancer cell signaling and enhancing chemotherapy efficacy through multiple mechanisms. Fenbendazole Fenbendazole, a benzimidazole anthelmintic, exhibits several anti-cancer effects: Microtubule disruption:  Fenbendazole acts as a moderate microtubule destabilizing agent, impairing microtubule polymerization which is critical for cancer cell division 4 6 . Metabolic interference:  It inhibits glucose uptake by downregulating GLUT1 transporters and hexokinase II (HKII), key components of glycolysis, thereby starving cancer cells of energy and reversing drug resistance 1 4 6 . Activation of p53 pathway:  Fenbendazole induces mitochondrial translocation of p53, promoting apoptosis and cell cycle arrest at the G2/M phase 1 2 4 . Induction of multiple cell death pathways:  It triggers apoptosis, necrosis, autophagy, and ferroptosis, includin...